Pacira BioSciences, Inc. (PCRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pacira BioSciences, Inc. (PCRX) has a cash flow conversion efficiency ratio of 0.086x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($57.46 Million) by net assets ($671.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Pacira BioSciences, Inc. for the company's overall valuation and market capitalisation.
Pacira BioSciences, Inc. - Cash Flow Conversion Efficiency Trend (2008–2025)
This chart illustrates how Pacira BioSciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pacira BioSciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pacira BioSciences, Inc. ranked by their cash flow conversion efficiency. Explore PCRX cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TAG Colonia-Immobilien AG
HM:KBU
|
N/A |
|
Shenzhen Sunrise New Energy Co Ltd
SHE:002256
|
0.036x |
|
Supalai Public Company Limited
BK:SPALI
|
0.027x |
|
Astra Otoparts Tbk
JK:AUTO
|
0.045x |
|
Southside Bancshares, Inc.
NYSE:SBSI
|
0.057x |
|
NTG Nordic Transport Group A/S
CO:NTG
|
-0.002x |
|
Hanmi Financial Corporation
NASDAQ:HAFC
|
-0.011x |
|
Sana Biotechnology Inc
NASDAQ:SANA
|
-0.212x |
Annual Cash Flow Conversion Efficiency for Pacira BioSciences, Inc. (2008–2025)
The table below shows the annual cash flow conversion efficiency of Pacira BioSciences, Inc. from 2008 to 2025. View PCRX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $693.11 Million | $151.99 Million | 0.219x | -9.88% |
| 2024-12-31 | $778.35 Million | $189.39 Million | 0.243x | +36.90% |
| 2023-12-31 | $870.13 Million | $154.65 Million | 0.178x | -5.18% |
| 2022-12-31 | $775.01 Million | $145.27 Million | 0.187x | +8.91% |
| 2021-12-31 | $730.41 Million | $125.72 Million | 0.172x | +38.46% |
| 2020-12-31 | $619.69 Million | $77.03 Million | 0.124x | -37.43% |
| 2019-12-31 | $354.94 Million | $70.52 Million | 0.199x | +30.59% |
| 2018-12-31 | $321.23 Million | $48.87 Million | 0.152x | +139.07% |
| 2017-12-31 | $279.48 Million | $17.79 Million | 0.064x | -58.35% |
| 2016-12-31 | $218.98 Million | $33.45 Million | 0.153x | +15.06% |
| 2015-12-31 | $218.39 Million | $29.00 Million | 0.133x | -10.78% |
| 2014-12-31 | $171.15 Million | $25.47 Million | 0.149x | +114.20% |
| 2013-12-31 | $41.25 Million | $-43.22 Million | -1.048x | +1.62% |
| 2012-12-31 | $65.86 Million | $-70.13 Million | -1.065x | -65.81% |
| 2011-12-31 | $48.27 Million | $-31.00 Million | -0.642x | -224.89% |
| 2010-12-31 | $-48.38 Million | $-24.88 Million | 0.514x | -43.37% |
| 2009-12-31 | $-22.95 Million | $-20.84 Million | 0.908x | +123.30% |
| 2008-12-31 | $7.49 Million | $-29.19 Million | -3.897x | -- |
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension ind… Read more